New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 10, 2014
10:01 EDTCNCE, HAR, LH, DGX, LINTA, HSNI, IBP, TLMR, EGRX, FLXNOn The Fly: Analyst Initiation Summary
Concert Pharmaceuticals (CNCE) initiated with a Buy at UBS and an Outperform at JMP Securities... Eagle Pharmaceuticals (EGRX) initiated with a Buy at Cantor and an Overweight at Piper Jaffray... Talmer Bancorp (TLMR) initiated with an Outperform at Keefe Bruyette, an Overweight at JPMorgan, a Strong Buy at Raymond James and an Outperform at RBC Capital... HSN, Inc. (HSNI) initiated with a Buy at UBS... Installed Building Products (IBP) initiated with a Buy at Deutsche Bank and a Neutral at SunTrust... Liberty Interactive (LINTA) initiated with a Buy at UBS and Craig-Hallum... Flexion (FLXN) initiated with a Buy at Needham... LabCorp (LH) assumed with a Neutral at Piper Jaffray... Quest Diagnostics (DGX) assumed with a Neutral at Piper Jaffray... Harman (HAR) initiated with an Outperform at Raymond James.
News For CNCE;EGRX;TLMR;IBP;HSNI;LINTA;DGX;LH;HAR;FLXN From The Last 14 Days
Check below for free stories on CNCE;EGRX;TLMR;IBP;HSNI;LINTA;DGX;LH;HAR;FLXN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2014
18:05 EDTLINTALiberty Interactive completes Liberty TripAdvisor Holdings spin-off
Subscribe for More Information
August 26, 2014
09:02 EDTCNCEConcert Pharmaceuticals achieves $2M milestone for AVP-786
Concert Pharmaceuticals (CNCE) announced that it has achieved a $2M milestone under its development and license agreement with Avanir Pharmaceuticals (AVNR) for the clinical progression of AVP-786. The milestone is a result of Avanir initiating dosing in a Phase 2 clinical trial with AVP-786 for the adjunctive treatment of major depressive disorder. The agreement provides Avanir with worldwide rights to develop and commercialize AVP-786 and other deuterium-modified dextromethorphan compounds. The licensed compounds are believed to have potential for the treatment of neurological and psychiatric disorders. Under the agreement, Concert is eligible to receive additional milestone payments based upon achievement of certain predefined clinical, regulatory and commercial targets. Avanir will continue to have overall responsibility for research, development and commercialization of d-DM compounds, including AVP-786, and Concert is eligible to receive tiered royalties on worldwide sales of any products containing d-DM. The milestone announced today is the second development milestone Concert has earned under the agreement.
August 25, 2014
16:33 EDTLINTALiberty sites when-issued trading for spin-off of Liberty TripAdvisor Holdings
Liberty Interactive (LINTA, LVNTA) announced that, in connection with its upcoming spin-off of its subsidiary Liberty TripAdvisor Holdings, it has been advised by Nasdaq that shares of TripAdvisor Holdings Series A and Series B common stock will trade on a when-issued basis on the Nasdaq Global Select Market under the symbols “LTPAV” and “LTPBV”, respectively, on August 27. The Spin-off will be effected through the distribution, by means of a dividend, of TripAdvisor Holdings common stock at 5:00 p.m., New York City time, on August 27 to holders of Liberty Ventures common stock. The record date for the dividend was 5:00 p.m., New York City time, on August 21. Liberty expects that the TripAdvisor Holdings Series A and Series B common stock will begin trading in the regular way on the Nasdaq Global Select Market under the symbols “LTRPA” and “LTRPB” beginning on August 28. The completion of the Spin-off remains subject to the satisfaction or waiver, as applicable, of a number of conditions.
09:19 EDTLINTATripAdvisor price target raised to $100 from $88 at Wunderlich
Subscribe for More Information
August 19, 2014
11:32 EDTLHLabCorp prenatal test a negative for Sequenom, says Maxim
Maxim views LabCorp's (LH) announcement today that it will begin offering the informaSeq prenatal test as a long-term negative for Sequenom (SQNM) due to increased competition. The news is also negative for Illumina (ILMN) and PerkinElmer (PKI), who both offer Non-Invasive Prenatal Tests, Maxim adds. The firm recommends buying shares of LabCorp and keeps a Buy rating on the name with a $130 price target.
08:47 EDTLHLabCorp announces availability of InformaSeq non-invasive prenatal test
Laboratory Corporation of America Holdings announced the availability of the informaSeq Prenatal Test. The informaSeq Prenatal Test is an advanced, non-invasive, next-generation prenatal screening assay that can assess risk for multiple fetal chromosomal aneuploidies, or abnormalities in the number of chromosomes, from a single maternal blood draw. There are testing options for several additional common sex-related aneuploidies. The test is offered through Integrated Genetics, part of the LabCorp Specialty Testing Group of laboratories that offer advanced esoteric and genomic testing.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use